Beyond Air : Corporate Presentation

Corporate Presentation

August 2022

Forward Looking Statements

This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the "Company") nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Company files annual, quarterly and other reports with the Securities and Exchange Commission (the "SEC") including its Annual Report on Form 10-K for the year ended March 31, 2022 (the "Form 10-K") which was filed on June 16, 2021. You may get these documents for free by visiting EDGAR on the SEC's website at www.sec.gov. For a more complete discussion of the risk factors affecting our business, please refer to the Form 10-K.

Our public communications, including this presentation, and SEC filings, may contain statements related to future, not past, events. These forward-looking statements are based upon current beliefs and expectations of Beyond Air's management and are subject to significant risks and uncertainties. These forward-looking statements often, but not always, may be identified by the use of words such as "believes," "estimates," "anticipates," "targets," "expects," "plans," "projects," "intends," "predicts," "may," "could," "might," "will," "should," "approximately," potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward- looking statements contain these words. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

These forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the patient market size and market adoption of our products by physicians and patients, the timing and cost of clinical trials for our products or whether such trials will be conducted at all, completion and receiving favorable results of clinical trials for our products, the development and approval of the use of nitric oxide for additional indications, FDA approval of, or other regulatory action with respect to, the timing, cost or other aspects of the commercial launch of our products and the commercial launch and future sales of our products or any other future products or product candidates. The extent to which the COVID-19 pandemic and global efforts to contain its spread will impact our operations, including the ability to conduct our preclinical studies and clinical trials or rely on our third-party manufacturing and supply chain, will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated or not at all. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this presentation.

2

Our Mission

Harness the Power of Nitric Oxide

Ability to transition between hospital use and untapped at-home market

Creating Unlimited Access to On-Demand Nitric Oxide from Ambient Air

Nasdaq Listed: XAIR

Headquarters: Garden City, NY

Other Locations: Ireland, Israel

3

LungFit® Platform Elicits Paradigm Shift for

Nitric Oxide Therapy

Our revolutionary LungFit® technology platform generates nitric oxide (NO) on-demand from ambient air and safely delivers it to patients to treat a variety of lung diseases

The LungFit® Systems are designed by the same inventors who developed the first nitric oxide delivery system and other systems in use worldwide

Hospital Setting	Hospital NICU Setting	At-Home Treatment
High concentration nitric oxide to treat	Low concentration nitric oxide for the	High concentration nitric oxide for the
community acquired viral pneumonia	treatment of term and near-term neonates	treatment of NTM and lung infections in
(including COVID-19) and bronchiolitis+	with hypoxic respiratory failure*	patients with underlying COPD+

*Commonly referred to as persistent pulmonary hypertension of the newborn or PPHN.

• +Caution: LungFit® PRO and LungFit® GO are investigational device, limited by federal (or United States) law to investigational use. High concentration iNO is defined as >80 ppm to <400 ppm. Low concentration is ≤80 ppm.

Introducing the Patented Ionizer™ Technology

The LungFit® PH is the first and only system with patented Ionizer technology that generates nitric oxide using room air, enabling the delivery of unlimited, on-demandnitric oxide regardless of dose or flow.

Oxygen	60 Watts	Nitric Oxide

NO2 Smart

Filter

		Nitrogen	Electrode	Nitrogen
	Main and Backup Ionizers			Dioxide
5	For illustrative purposes.